publication . Article . Other literature type . 2018

Current Alzheimer's disease clinical trials: methods and placebo outcomes.

Schneider, Lon S.; Sano, Mary;
  • Published: 13 Nov 2018
Abstract Background Eighteen-month-long randomized, placebo-controlled clinical trials are common for phase II and phase III drug development for Alzheimer's disease (AD). Yet, no 18-month trial has shown statistically significant outcomes favoring the test drug. We examined characteristics and underlying assumptions of these trials by assessing the placebo groups. Methods We searched the registry for randomized, placebo-controlled clinical trials for AD of at least 18-month duration and extracted demographic, clinical, and trials characteristics, and change in main outcomes from the placebo groups. We obtained additional information from pres...
free text keywords: Health Policy, Developmental Neuroscience, Epidemiology, Cellular and Molecular Neuroscience, Geriatrics and Gerontology, Psychiatry and Mental health, Clinical Neurology, Placebo, Drug development, Clinical trial, Alzheimer's disease, medicine.disease, medicine, Memantine, medicine.drug, business.industry, business, Diabetes mellitus, Psychiatry, medicine.medical_specialty, Activities of daily living, Sample size determination, Article
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue